Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 451

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 451
---
 related to professional services, employee payroll, directors’ and officers’ insurance, information technology, marketing and communication, and travel.

238 Merger transaction costs Our Merger transaction costs totaled $743,838 for the year ended December31, 2024, compared to $0 for the year ended December31, 2023. These costs were primarily attributable to increase in legal counsel, audit and accounting fees related to the ongoing Merger transaction. Operating Loss As a result of the foregoing, our operating loss totaled $4,380,113 for the year ended December31, 2024, representing a decrease of $7,426,950 or 63%, compared to $11,807,063 for the year ended December31, 2023. Our operating loss reflects ongoing investment in R&D and clinical trials as we advance our pipeline along with general and administrative operational costs. Other Income for Termination of EF License Agreement Other income for termination of EF License Agreement for the year ended December31, 2024 was $2.5million. On August28, 2024, we agreed with Eurofarma to terminate the EF License Agreement effective September30, 2024 and we recognized $2.5million from the EF License Agreement as Other income for termination of EF License Agreement. This termination reflects a change in the Company’s strategic direction, as management has decided to discontinue the development and commercialization of its product candidate, Nolazol, in Latin American countries through a strategic partnership with Eurofarma, a Brazilian pharmaceutical company. Other Income (Expense), net Other income (expense) consists of exchange rate differences. We recognized other income of $49,351 for the year ended December31, 2024, representing a decrease of $269,163, or 122%, compared to Other expense $219,812 for the year ended December31, 2023. The increase in Other income, net was attributable to favorable exchange rate differences. Interest Expense Interest expense was $45,054, for the year ended December31, 2024 representing a decrease of $74,866, or 62%, compared to expense of $119,920, for the year ended December31, 2023. The decrease was due to less interest due to from notes payable no longer outstanding. Interest on Related Party Loans Interest on related party loans was $104,963, for the year ended December31, 2024 representing an increase of $79,730, or 316%, compared to expense of $25,